{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:45:59Z","timestamp":1792698359347,"version":"4.5.0"},"reference-count":51,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0772-0","type":"journal-article","created":{"date-parts":[[2019,12,4]],"date-time":"2019-12-04T20:03:03Z","timestamp":1575489783000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Functional characterization of the selective pan-allele anti-SIRP\u03b1 antibody ADU-1805 that blocks the SIRP\u03b1\u2013CD47 innate immune checkpoint"],"prefix":"10.1136","volume":"7","author":[{"given":"Erik","family":"Voets","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Parad\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lutje Hulsik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne","family":"Spijkers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wout","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost","family":"Rens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge","family":"Reinieren-Beeren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"van den Tillaart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander","family":"van Duijnhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian","family":"Driessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"Habraken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"van Zandvoort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost","family":"Kreijtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Vink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2966-114X","authenticated-orcid":false,"given":"Andrea","family":"van Elsas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"van Eenennaam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,12,4]]},"reference":[{"issue":"1","key":"772_CR1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/imr.12527","volume":"276","author":"HL Matlung","year":"2017","unstructured":"Matlung HL, Szilagyi K, Barclay NA, van den Berg TK. The CD47-SIRP\u03b1 signaling axis as an innate immune checkpoint in cancer. Immunol Rev. 2017;276(1):145\u201364.","journal-title":"Immunol Rev"},{"issue":"2","key":"772_CR2","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1164\/rccm.200711-1661OC","volume":"178","author":"WJ Janssen","year":"2008","unstructured":"Janssen WJ, McPhillips KA, Dickinson MG, Linderman DJ, Morimoto K, Xiao YQ, et al. Surfactant proteins a and D suppress alveolar macrophage phagocytosis via interaction with SIRP\u03b1. Am J Respir Crit Care Med. 2008;178(2):158\u201367.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"772_CR3","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1074\/jbc.274.2.559","volume":"274","author":"P Jiang","year":"1999","unstructured":"Jiang P, Lagenaur CF, Narayanan V. Integrin-associated protein is a ligand for the P84 neural adhesion molecule. J Biol Chem. 1999;274(2):559\u201362.","journal-title":"J Biol Chem"},{"issue":"5473","key":"772_CR4","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1126\/science.288.5473.2051","volume":"288","author":"PA Oldenborg","year":"2000","unstructured":"Oldenborg PA, Zheleznyak A, Fang YF, Lagenaur CF, Gresham HD, Lindberg FP. Role of CD47 as a marker of self on red blood cells. Science. 2000;288(5473):2051\u20134.","journal-title":"Science"},{"issue":"42","key":"772_CR5","doi-asserted-by":"crossref","first-page":"39833","DOI":"10.1074\/jbc.M203287200","volume":"277","author":"T Yamao","year":"2002","unstructured":"Yamao T, Noguchi T, Takeuchi O, Nishiyama U, Morita H, Hagiwara T, et al. Negative regulation of platelet clearance and of the macrophage phagocytic response by the Transmembrane glycoprotein SHPS-1. J Biol Chem. 2002;277(42):39833\u20139.","journal-title":"J Biol Chem"},{"issue":"2","key":"772_CR6","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","volume":"138","author":"R Majeti","year":"2009","unstructured":"Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009;138(2):286\u201399.","journal-title":"Cell"},{"issue":"5","key":"772_CR7","first-page":"781","volume":"76","author":"LG Poels","year":"1986","unstructured":"Poels LG, Peters D, van Megen Y, Vooijs GP, Verheyen RN, Willemen A, et al. Monoclonal antibody against human ovarian tumor-associated antigens. J Natl Cancer Inst. 1986;76(5):781\u201391.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"772_CR8","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","volume":"142","author":"MP Chao","year":"2010","unstructured":"Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell. 2010;142(5):699\u2013713.","journal-title":"Cell"},{"issue":"12","key":"772_CR9","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1038\/leu.2012.141","volume":"26","author":"D Kim","year":"2012","unstructured":"Kim D, Wang J, Willingham SB, Martin R, Wernig G, Weissman IL. Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells. Leukemia. 2012;26(12):2538\u201345.","journal-title":"Leukemia"},{"key":"772_CR10","doi-asserted-by":"crossref","first-page":"29719","DOI":"10.1038\/srep29719","volume":"6","author":"H Zhao","year":"2016","unstructured":"Zhao H, Wang J, Kong X, Li E, Liu Y, Du X, et al. CD47 promotes tumor invasion and metastasis in non-small cell lung Cancer. Sci Rep. 2016;6:29719.","journal-title":"Sci Rep"},{"issue":"17","key":"772_CR11","doi-asserted-by":"crossref","first-page":"6662","DOI":"10.1073\/pnas.1121623109","volume":"109","author":"SB Willingham","year":"2012","unstructured":"Willingham SB, Volkmer J-P, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A. 2012;109(17):6662\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"45","key":"772_CR12","doi-asserted-by":"crossref","first-page":"18342","DOI":"10.1073\/pnas.1106550108","volume":"108","author":"XW Zhao","year":"2011","unstructured":"Zhao XW, van Beek EM, Schornagel K, der Maaden HV, Houdt MV, Otten MA, et al. CD47\u2013signal regulatory protein-\u03b1 (SIRP\u03b1) interactions form a barrier for antibody-mediated tumor cell destruction. Proc Natl Acad Sci. 2011;108(45):18342\u20137.","journal-title":"Proc Natl Acad Sci"},{"issue":"6141","key":"772_CR13","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1126\/science.1238856","volume":"341","author":"K Weiskopf","year":"2013","unstructured":"Weiskopf K, Ring AM, Ho CCM, Volkmer J-P, Levin AM, Volkmer AK, et al. Engineered SIRP\u03b1 variants as immunotherapeutic adjuvants to anticancer antibodies. Science. 2013;341(6141):88\u201391.","journal-title":"Science"},{"issue":"8","key":"772_CR14","doi-asserted-by":"crossref","first-page":"e0201832","DOI":"10.1371\/journal.pone.0201832","volume":"13","author":"SE Kauder","year":"2018","unstructured":"Kauder SE, Kuo TC, Harrabi O, Chen A, Sangalang E, Doyle L, et al. ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile. PLoS One. 2018;13(8):e0201832.","journal-title":"PLoS One"},{"issue":"10","key":"772_CR15","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/nm.3931","volume":"21","author":"X Liu","year":"2015","unstructured":"Liu X, Pu Y, Cron K, Deng L, Kline J, Frazier WA, et al. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat Med. 2015;21(10):1209\u201315.","journal-title":"Nat Med"},{"issue":"23","key":"772_CR16","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1158\/0008-5472.CAN-14-0037-T","volume":"74","author":"DR Soto-Pantoja","year":"2014","unstructured":"Soto-Pantoja DR, Terabe M, Ghosh A, Ridnour LA, DeGraff WG, Wink DA, et al. CD47 in the tumor microenvironment limits cooperation between antitumor T-cell immunity and radiotherapy. Cancer Res. 2014;74(23):6771\u201383.","journal-title":"Cancer Res"},{"issue":"2","key":"772_CR17","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/hep.27859","volume":"62","author":"J Lo","year":"2015","unstructured":"Lo J, Lau EYT, Ching RHH, Cheng BYL, Ma MKF, Ng IOL, et al. Nuclear factor kappa B\u2013mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice. Hepatology. 2015;62(2):534\u201345.","journal-title":"Hepatology"},{"issue":"19","key":"772_CR18","doi-asserted-by":"crossref","first-page":"E2646","DOI":"10.1073\/pnas.1604268113","volume":"113","author":"Jonathan T. Sockolosky","year":"2016","unstructured":"Sockolosky JT, Dougan M, Ingram JR, Ho CCM, Kauke MJ, Almo SC, et al. Durable antitumor responses to CD47 blockade require adaptive immune stimulation. Proc Natl Acad Sci U S A. 2016;113:E2646-54.","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"8","key":"772_CR19","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/j.celrep.2018.07.062","volume":"24","author":"X Liu","year":"2018","unstructured":"Liu X, Liu L, Ren Z, Yang K, Xu H, Luan Y, et al. Dual targeting of innate and adaptive checkpoints on tumor cells limits immune evasion. Cell Rep. 2018;24(8):2101\u201311.","journal-title":"Cell Rep"},{"issue":"18","key":"772_CR20","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","volume":"379","author":"R Advani","year":"2018","unstructured":"Advani R, Flinn I, Popplewell L, Forero A, Bartlett NL, Ghosh N, et al. CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin\u2019s lymphoma. N Engl J Med. 2018;379(18):1711\u201321.","journal-title":"N Engl J Med"},{"issue":"5","key":"772_CR21","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/CCO.0000000000000468","volume":"30","author":"AS Folkes","year":"2018","unstructured":"Folkes AS, Feng M, Zain JM, Abdulla F, Rosen ST, Querfeld C. Targeting CD47 as a cancer therapeutic strategy: the cutaneous T-cell lymphoma experience. Curr Opin Oncol. 2018;30(5):332\u20137.","journal-title":"Curr Opin Oncol"},{"key":"772_CR22","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1200\/JCO.18.02018","volume":"37","author":"BI Sikic","year":"2019","unstructured":"Sikic BI, Lakhani N, Patnaik A, Shah SA, Chandana SR, Rasco D, et al. First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers. J Clin Oncol. 2019;37:946\u201353 JCO.18.02018.","journal-title":"J Clin Oncol"},{"issue":"2","key":"772_CR23","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1083\/jcb.135.2.533","volume":"135","author":"AG Gao","year":"1996","unstructured":"Gao AG, Lindberg FP, Dimitry JM, Brown EJ, Frazier WA. Thrombospondin modulates alpha v beta 3 function through integrin-associated protein. J Cell Biol. 1996;135(2):533\u201344.","journal-title":"J Cell Biol"},{"issue":"14","key":"772_CR24","doi-asserted-by":"crossref","first-page":"22406","DOI":"10.18632\/oncotarget.9899","volume":"8","author":"L Gao","year":"2016","unstructured":"Gao L, Chen K, Gao Q, Wang X, Sun J, Yang Y-G, et al. CD47 deficiency in tumor stroma promotes tumor progression by enhancing angiogenesis. Oncotarget. 2016;8(14):22406\u201313.","journal-title":"Oncotarget"},{"issue":"1","key":"772_CR25","doi-asserted-by":"crossref","first-page":"e89140","DOI":"10.1172\/jci.insight.89140","volume":"2","author":"T Yanagita","year":"2017","unstructured":"Yanagita T, Murata Y, Tanaka D, Motegi S-I, Arai E, Daniwijaya EW, et al. Anti-SIRP\u03b1 antibodies as a potential new tool for cancer immunotherapy. JCI Insight. 2017;2(1):e89140.","journal-title":"JCI Insight"},{"issue":"12","key":"772_CR26","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/ni1527","volume":"8","author":"K Takenaka","year":"2007","unstructured":"Takenaka K, Prasolava TK, Wang JCY, Mortin-Toth SM, Khalouei S, Gan OI, et al. Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells. Nat Immunol. 2007;8(12):1313\u201323.","journal-title":"Nat Immunol"},{"issue":"4","key":"772_CR27","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.4049\/jimmunol.173.4.2562","volume":"173","author":"G Brooke","year":"2004","unstructured":"Brooke G, Holbrook JD, Brown MH, Barclay AN. Human lymphocytes interact directly with CD47 through a novel member of the signal regulatory protein (SIRP) family. J Immunol. 2004;173(4):2562\u201370.","journal-title":"J Immunol"},{"issue":"25","key":"772_CR28","doi-asserted-by":"crossref","first-page":"6856","DOI":"10.1182\/blood-2011-01-330852","volume":"117","author":"M Guadagnoli","year":"2011","unstructured":"Guadagnoli M, Kimberley FC, Phan U, Cameron K, Vink PM, Rodermond H, et al. Development and characterization of APRIL antagonistic monoclonal antibodies for treatment of B-cell lymphomas. Blood. 2011;117(25):6856\u201365.","journal-title":"Blood"},{"issue":"24","key":"772_CR29","doi-asserted-by":"crossref","first-page":"10029","DOI":"10.1073\/pnas.86.24.10029","volume":"86","author":"C Queen","year":"1989","unstructured":"Queen C, Schneider WP, Selick HE, Payne PW, Landolfi NF, Duncan JF, et al. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci. 1989;86(24):10029\u201333.","journal-title":"Proc Natl Acad Sci"},{"key":"772_CR30","first-page":"201710877","volume":"20","author":"NG Ring","year":"2017","unstructured":"Ring NG, Herndler-Brandstetter D, Weiskopf K, Shan L, Volkmer J-P, George BM, et al. Anti-SIRP\u03b1 antibody immunotherapy enhances neutrophil and macrophage antitumor activity. Proc Natl Acad Sci. 2017;20:201710877.","journal-title":"Proc Natl Acad Sci"},{"issue":"2","key":"772_CR31","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.molcel.2008.05.026","volume":"31","author":"D Hatherley","year":"2008","unstructured":"Hatherley D, Graham SC, Turner J, Harlos K, Stuart DI, Barclay AN. Paired receptor specificity explained by structures of signal regulatory proteins alone and Complexed with CD47. Mol Cell. 2008;31(2):266\u201377.","journal-title":"Mol Cell"},{"issue":"1","key":"772_CR32","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.bcmd.2010.02.016","volume":"45","author":"RK Tsai","year":"2010","unstructured":"Tsai RK, Rodriguez PL, Discher DE. Self inhibition of phagocytosis: the affinity of \u201cmarker of self\u201d CD47 for SIRPalpha dictates potency of inhibition but only at low expression levels. Blood Cells Mol Dis. 2010;45(1):67\u201374.","journal-title":"Blood Cells Mol Dis"},{"issue":"2","key":"772_CR33","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0012-1606(90)90249-I","volume":"137","author":"W Chuang","year":"1990","unstructured":"Chuang W, Lagenaur CF. Central nervous system antigen P84 can serve as a substrate for neurite outgrowth. Dev Biol. 1990;137(2):219\u201332.","journal-title":"Dev Biol"},{"issue":"1","key":"772_CR34","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/imr.12350","volume":"268","author":"P Bruhns","year":"2015","unstructured":"Bruhns P, J\u00f6nsson F. Mouse and human FcR effector functions. Immunol Rev. 2015;268(1):25\u201351.","journal-title":"Immunol Rev"},{"issue":"16","key":"772_CR35","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1182\/blood-2008-09-179754","volume":"113","author":"P Bruhns","year":"2009","unstructured":"Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, et al. Specificity and affinity of human Fc\u03b3 receptors and their polymorphic variants for human IgG subclasses. Blood. 2009;113(16):3716\u201325.","journal-title":"Blood"},{"issue":"1","key":"772_CR36","doi-asserted-by":"crossref","first-page":"140","DOI":"10.4049\/jimmunol.131.1.140","volume":"131","author":"RJ Kurlander","year":"1983","unstructured":"Kurlander RJ. Blockade of fc receptor-mediated binding to U-937 cells by murine monoclonal antibodies directed against a variety of surface antigens. J Immunol. 1983;131(1):140\u20137.","journal-title":"J Immunol"},{"issue":"13","key":"772_CR37","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.1016\/j.celrep.2018.05.082","volume":"23","author":"HL Matlung","year":"2018","unstructured":"Matlung HL, Babes L, Zhao XW, van Houdt M, Treffers LW, van Rees DJ, et al. Neutrophils Kill Antibody-Opsonized Cancer Cells by Trogoptosis. Cell Rep. 2018;23(13):3946\u20133959.e6.","journal-title":"Cell Rep"},{"issue":"6","key":"772_CR38","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1182\/blood-2004-07-2823","volume":"105","author":"L Piccio","year":"2005","unstructured":"Piccio L, Vermi W, Boles KS, Fuchs A, Strader CA, Facchetti F, et al. Adhesion of human T cells to antigen-presenting cells through SIRP\u03b22-CD47 interaction costimulates T-cell proliferation. Blood. 2005;105(6):2421\u20137.","journal-title":"Blood"},{"issue":"1","key":"772_CR39","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1084\/jem.168.1.127","volume":"168","author":"CI Bindon","year":"1988","unstructured":"Bindon CI, Hale G, Br\u00fcggemann M, Waldmann H. Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q. J Exp Med. 1988;168(1):127\u201342.","journal-title":"J Exp Med"},{"issue":"9","key":"772_CR40","doi-asserted-by":"crossref","first-page":"e0137345","DOI":"10.1371\/journal.pone.0137345","volume":"10","author":"J Liu","year":"2015","unstructured":"Liu J, Wang L, Zhao F, Tseng S, Narayanan C, Shura L, et al. Pre-clinical development of a humanized anti-CD47 antibody with anti-Cancer therapeutic potential. PLoS One. 2015;10(9):e0137345.","journal-title":"PLoS One"},{"issue":"2","key":"772_CR41","doi-asserted-by":"crossref","first-page":"e536","DOI":"10.1038\/bcj.2017.7","volume":"7","author":"EC Pietsch","year":"2017","unstructured":"Pietsch EC, Dong J, Cardoso R, Zhang X, Chin D, Hawkins R, et al. Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies. Blood Cancer J. 2017;7(2):e536.","journal-title":"Blood Cancer J"},{"issue":"63","key":"772_CR42","first-page":"63ra94","volume":"2","author":"MP Chao","year":"2010","unstructured":"Chao MP, Jaiswal S, Weissman-Tsukamoto R, Alizadeh AA, Gentles AJ, Volkmer J, et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med. 2010;2(63):63ra94.","journal-title":"Sci Transl Med"},{"issue":"22","key":"772_CR43","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1182\/blood.V128.22.1812.1812","volume":"128","author":"S Ansell","year":"2016","unstructured":"Ansell S, Chen RW, Flinn IW, Maris MB, O\u2019Connor OA, Johnson LD, et al. A phase 1 study of TTI-621, a novel immune checkpoint inhibitor targeting CD47, in patients with relapsed or refractory hematologic malignancies. Blood. 2016;128(22):1812.","journal-title":"Blood"},{"issue":"1","key":"772_CR44","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/bph.12904","volume":"172","author":"K K\u00f6ck","year":"2015","unstructured":"K\u00f6ck K, Pan WJ, Gow JM, Horner MJ, Gibbs JP, Colbert A, et al. Preclinical development of AMG 139, a human antibody specifically targeting IL-23. Br J Pharmacol. 2015;172(1):159\u201372.","journal-title":"Br J Pharmacol"},{"issue":"7769","key":"772_CR45","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41586-019-1456-0","volume":"572","author":"AA Barkal","year":"2019","unstructured":"Barkal AA, Brewer RE, Markovic M, Kowarsky M, Barkal SA, Zaro BW, et al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature. 2019;572(7769):392\u20136.","journal-title":"Nature"},{"issue":"2","key":"772_CR46","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1042\/bj3550489","volume":"355","author":"J Munday","year":"2001","unstructured":"Munday J, Sheena K, Jian NI, Cornish AL, Zhang JQ, Nicoll G, et al. Identification, characterization and leucocyte expression of Siglec-10, a novel human sialic acid-binding receptor. Biochem J. 2001;355(2):489\u201397.","journal-title":"Biochem J"},{"issue":"11","key":"772_CR47","doi-asserted-by":"crossref","first-page":"5345","DOI":"10.4049\/jimmunol.159.11.5345","volume":"159","author":"M Waclavicek","year":"1997","unstructured":"Waclavicek M, Majdic O, Stulnig T, Berger M, Baumruker T, Knapp W, et al. T cell stimulation via CD47: agonistic and antagonistic effects of CD47 monoclonal antibody 1\/1A4. J Immunol. 1997;159(11):5345\u201354.","journal-title":"J Immunol"},{"issue":"9","key":"772_CR48","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1182\/blood.V97.9.2741","volume":"97","author":"M Seiffert","year":"2001","unstructured":"Seiffert M, Brossart P, Cant C, Cella M, Colonna M, Brugger W, et al. Signal-regulatory protein alpha (SIRPalpha) but not SIRPbeta is involved in T-cell activation, binds to CD47 with high affinity, and is expressed on immature CD34(+)CD38(\u2212) hematopoietic cells. Blood. 2001;97(9):2741\u20139.","journal-title":"Blood"},{"issue":"2","key":"772_CR49","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1189\/jlb.3A1215-546RR","volume":"101","author":"V Azcutia","year":"2017","unstructured":"Azcutia V, Bassil R, Herter JM, Engelbertsen D, Newton G, Autio A, et al. Defects in CD4+ T cell LFA-1 integrin-dependent adhesion and proliferation protect Cd47\u2212\/\u2212 mice from EAE. J Leukoc Biol. 2017;101(2):493\u2013505.","journal-title":"J Leukoc Biol"},{"issue":"5","key":"772_CR50","doi-asserted-by":"crossref","first-page":"736","DOI":"10.4161\/mabs.25743","volume":"5","author":"H Haegel","year":"2013","unstructured":"Haegel H, Thioudellet C, Hallet R, Geist M, Menguy T, Le Pogam F, et al. A unique anti-CD115 monoclonal antibody which inhibits osteolysis and skews human monocyte differentiation from M2-polarized macrophages toward dendritic cells. MAbs. 2013;5(5):736\u201347.","journal-title":"MAbs"},{"issue":"13","key":"772_CR51","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1158\/1078-0432.CCR-16-3122","volume":"23","author":"JM Brown","year":"2017","unstructured":"Brown JM, Recht L, Strober S. The promise of targeting macrophages in Cancer therapy. Clin Cancer Res. 2017;23(13):3241\u201350.","journal-title":"Clin Cancer Res"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0772-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0772-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0772-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T17:07:10Z","timestamp":1695488830000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0772-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["772"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0772-0","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"6 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The welfare of the mice was maintained in accordance with the general principles governing the use of animals in experiments of the European Communities (Directive 2010\/63\/EU) and Dutch legislation (The revised Experiments on Animals Act, 2014). This included licensing of the project by the Central Committee on Animal Experimentation (project license 3721) and approval of the study by the Triskelion Animal Welfare Body (AWB number TRIS-200).The NHP study was performed in compliance with the German Animal Welfare Act and was approved by the local IACUC (applied for by Covance Preclinical Services GmbH). This study was performed in consideration of the DIRECTIVE 2010\/63\/EU OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 22 September 2010 on the protection of animals used for scientific purposes. In addition, this study was performed in consideration of the Commission Recommendation 2007\/526\/EC on guidelines for the accommodation and care of animals used for experimental and other scientific purposes (Appendix A of Convention ETS 123).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have been or are employees of Aduro Biotech, Inc. and have stocks and\/or stock options in Aduro Biotech, Inc. The authors do not have any financial competing interests. EV, PV, DLH, AvE and HvE have filed a patent application (WO2018\/190719) that describes the invention of the anti-SIRP\u03b1 antibody hSIRP\u03b1.40A and its humanized variant ADU-1805. All the company-employed authors declare that their employment does not alter their adherence to the policies of Journal for Immunotherapy of Cancer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"340"}}